SRR9879279
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.520
- TGF_BETA_SIGNALING+0.520
- MITOTIC_SPINDLE+0.470
- PROTEIN_SECRETION+0.410
- MTORC1_SIGNALING+0.400
- DNA_REPAIR+0.350
- GLYCOLYSIS+0.350
Top 10 suppressed
- KRAS_SIGNALING_DN-0.300
- XENOBIOTIC_METABOLISM-0.300
- ALLOGRAFT_REJECTION-0.200
- MYOGENESIS-0.200
- BILE_ACID_METABOLISM-0.190
- IL6_JAK_STAT3_SIGNALING-0.150
- FATTY_ACID_METABOLISM-0.130
- INFLAMMATORY_RESPONSE-0.130
- HEME_METABOLISM-0.090
- IL2_STAT5_SIGNALING-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.878 |
| 2 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.873 |
| 3 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.861 |
| 4 | TCGA-GD-A3OQ-01A-32R-A220-07 | — | — | 0.858 |
| 5 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.856 |
| 6 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.854 |
| 7 | SRR934935 | — | — | 0.852 |
| 8 | TCGA-CR-6493-01A-11R-1873-07 | — | — | 0.848 |
| 9 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.848 |
| 10 | SRR934967 | — | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.520 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |